국가임상시험지원재단

페이스북 유튜브

유관기관 바로가기

유관기관 바로가기

정부/공공기관: 보건복지부; 식품의약품안전처; 질병관리청; 국민건강보험공단; 한국보건산업진흥원; 건강보험심사평가원; 국립보건연구원; 국립암센터; 식품의약품안전평가원; 한국보건의료정보원; 국세청; 한국보건복지인재원; 한국의약품안전관리원; 한국보건의료연구원; 오송첨단의료산업진흥재단; 대구경북첨단의료산업진흥재단; 재단법인 국가생명윤리정책원

임상시험센터: CHA 의과대학교 분당차병원; 가천대길병원; 가톨릭대학교 서울성모병원; 강남세브란스병원; 강동경희대학교병원; 건국대학교병원; 경북대학교병원; 경희대학교병원; 고려대학교 의과대학 부속 구로병원; 고려대학교안암병원; 동국대학교일산불교병원; 동아대학교병원; 베스티안병원; 부산대학교병원; 분당서울대학교병원; 삼성서울병원; 서울대학교병원; 서울아산병원; 세브란스병원; 아주대학교병원; 양지병원; 원광대학교병원; 김포우리병원

이화여자대학교 의과대학 부속 목동병원

인제대학교 부산백병원

인하대학교 의과대학부속병원

전남대학교병원

전북대학교병원

중앙대학교광명병원

충남대학교병원

충북대학교병원

울산대학교병원

한림대학교성심병원

한양대학교병원

원주세브란스기독병원

양산부산대학교병원

한국의약연구소

㈜엘에스케이글로벌파마서비스

㈜메디칼리써치

㈜프라임코어컨설팅

씨알에스큐브

㈜해밀턴씨에스

인바이츠바이오코아㈜

대한항암요법연구회

㈜디티앤사노메딕스

㈜아리바이오에이치앤비

㈜휴먼피부임상시험센터

㈜이피에스인터내셔널코리아

㈜지아이비타

㈜엠바이오

인투인월드

㈜리서치멘토

위키씨알오

주식회사 세이프소프트

㈜에버트라이

㈜셀타스퀘어

주식회사 아리비앤씨

스페로 주식회사

㈜지알케이파트너스

㈜에비드넷

주식회사 더웨이헬스케어

㈜메디플렉서스

㈜드림씨아이에스

주식회사리니칼코리아

주식회사 컨설팅바로

클리니젠코리아 유한회사

(주)비엑스플랜트

주식회사 제이앤피메디

주식회사 미라클러스

벡코씨알오 주식회사

㈜시믹코리아

주식회사 카카오헬스케어

분석CRO/센트럴랩: ㈜프로메디스; GCCL; SCL헬스케어; SML메디트리; 케일럽 멀티랩; (주)바이오메디앙; (주)디티앤씨알오; 인바이츠바이오코아㈜; ㈜엠바이오; ㈜마크로젠; ㈜리서치멘토; ㈜이원생명과학연구원; 휴사이언스; 넥시오랩; 뉴로핏 주식회사; 이원의료재단; 의료법인 유투의료재단; 주식회사 프라임헬스케어

유관기관/협회: 국가신약개발재단; (사)한국임상CRO협회; 대한CRC협의회(KACRC); 대한기관윤리심의기구협의회; 대한임상시험센터협의회(KACTC); 한국글로벌의약산업협회; 한국바이오의약품협회; 한국바이오협회; 한국신약개발연구조합; 한국제약바이오협회; 재생의료진흥재단; 한국규제과학센터; 한국병원약사회; 사단법인 한국에프디시규제과학회

학회/학교: 대한간학회; 대한감염학회; 대한암학회; 대한의학회; 대한임상약리학회; 대한항암요법연구회; 아주대학교 제약임상대학원; 한국임상개발연구회; 한국제약의학회; 대한소아혈액종양학회

정보서비스: 의약품통합정보시스템
(식품의약품안전처); 국가건강정보포털
(질병관리청); 임상연구정보서비스
(질병관리청); 의료기기정보포털
(식품의약품안전처); 제약산업정보포털
(한국보건산업진흥원); 희귀질환헬프라인
(질병관리청); 임상진료지침정보센터
(대한의학회)

해외 유관 기관: 정부 규제기관; (미국) FDA(U.S. Food & Drug Administration); (중국) NMPA(National Medical Products Administration); (유럽) EMA(European Medicines Agency); (영국) MHRA(Medicines & Healthcare products Regulatory Agency); (캐나다) Health Canada; (호주) TGA(Therapeutic Goods Administration); (인도) CDSCO(Central Drugs Standard Control Organization); (일본) MHLW(Ministry of Health, Labour, and Welfare); (일본) PMDA(Pharmaceuticals & Medical Devices Agency); (싱가폴) HSA(Health Sciences Authority); (대만) TFDA(Taiwan Food and Drug Administration); (홍콩) DO(Drug Office); (태국) FDA Thailand; (베트남) DAV(Drug Administration of Vietnam); (인도네시아) NA-DFC(Indonesia National Agency of Drug and Food Control); (인도네시아) BPOM(Badan Pengawas Obat dan Makanan)

지원 기관

(미국) ACRES(Alliance for Clinical Research Excellence and Safety)

(미국) AARHPP(Association for the Accreditation of Human Research Protection Program)

(미국) ACRP(Association of Clinical Research Professionals)

(미국) CenterWatch

(미국) DIA(Drug Information Association)

(미국) NIH(National Institutes of Health)

(미국) NCI(National Cancer Institute)

(미국) MIT CRITICAL DATA

(미국) TransCelerate

(유럽) ECRIN(European Clinical Research Infrastructure Network)

(영국) UKCRC(UK Clinical Research Collaboration)

(영국) NIHR(National Institute for Health Research)

(호주) Australian Clinical Trials

(일본) TRI(Translational Research Informatics Center)

(일본) AMED(Japan Agency for Medical Research and Development)

(싱가폴) SCRI(Singapore Clinical Research Institute)

(네덜란드) IFAPP(International Federation of Associations of Pharmaceutical Physicians)

(사우디아라비아) KAIMRC(King Abdullah International Medical Research Center)

정부/공공기관: 보건복지부; 식품의약품안전처; 질병관리청; 국민건강보험; 한국보건산업진흥원; 건강보험심사평가원; 국립보건연구원; 국립암센터; 식품의약품안전평가원; 한국보건의료정보원; 국세청; 한국보건복지인재원; 한국의약품안전관리원; 한국보건의료연구원; 오송첨단의료산업진흥재단; 대구경북첨단의료산업진흥재단; 재단법인 국가생명윤리정책원

임상시험센터: CHA 의과대학교 분당차병원; 가천대길병원; 가톨릭대학교 서울성모병원; 강남세브란스병원; 강동경희대학교병원; 건국대학교병원; 경북대학교병원; 경희대학교병원; 고려대학교 의과대학 부속 구로병원; 고려대학교안암병원; 동국대학교일산불교병원; 동아대학교병원; 베스티안병원; 부산대학교병원; 분당서울대학교병원; 삼성서울병원; 서울대학교병원; 서울아산병원; 세브란스병원; 아주대학교병원; 양지병원; 원광대학교병원; 이화여자대학교의과대학부속목동병원; 인제대학교 부산백병원; 인하대학교 의과대학부속병원; 전남대학교병원; 전북대학교병원; 중앙대학교광명병원; 충남대학교병원; 충북대학교병원; 울산대학교병원; 한림대학교성심병원; 한양대학교병원; 부민병원; 원주세브란스기독병원; 양산부산대학교병원

CRO: ㈜코랩; ㈜프로메디스; ㈜프리모생명과학; KH메디케어; 디투에스; 메디칼엑셀런스; 베데스다소프트; 사이넥스; 사이클룩스; 서울CRO; 심유; 씨씨앤아이리서치; ㈜씨엔알리서치; 알엔디모티브; 현대에이디엠코리아(주); 올리브헬스케어; 움트; ㈜메디헬프라인; ㈜엘에스케이글로벌파마서비스; 케일럽 멀티랩; 클립스비엔씨㈜; 파마크로; (주)헬프트라이알; 클루피주식회사; 네오뉴트라; 스누빛; 한국의약연구소; 굳빙센터; ㈜엘에스케이글로벌파마서비스; ㈜메디팁; ㈜메디칼리써치; ㈜프라임코어컨설팅; 씨알에스큐브; ㈜해밀턴씨에스; 인바이츠바이오코아㈜; 대한항암요법연구회; ㈜디티앤사노메딕스; ㈜아리바이오에이치앤비; ㈜휴먼피부임상시험센터; ㈜이피에스인터내셔널코리아; ㈜지아이비타; ㈜엠바이오; 인투인월드; ㈜리서치멘토; ㈜드림씨아이에스; 주식회사리니칼코리아; 주식회사 컨설팅바로; 클리니젠코리아 유한회사; (주)비엑스플랜트; 주식회사 제이앤피메디; 주식회사 미라클러스; 벡코씨알오 주식회사; ㈜시믹코리아; 주식회사 카카오헬스케어

분석CRO/센트럴랩: ㈜프로메디스; GCCL; SCL헬스케어; SML메디트리; 케일럽 멀티랩; (주)바이오메디앙; (주)디티앤씨알오; 인바이츠바이오코아㈜; ㈜엠바이오; ㈜마크로젠; ㈜리서치멘토; 넥시오랩; 뉴로핏 주식회사; 이원의료재단; 의료법인 유투의료재단; 주식회사 프라임헬스케어

유관기관/협회: 국가신약개발재단; (사)한국임상CRO협회; 대한CRC협의회(KACRC); 대한기관윤리심의기구협의회; 대한임상시험센터협의회(KACTC); 한국글로벌의약산업협회; 한국바이오의약품협회; 한국바이오협회; 한국신약개발연구조합; 한국제약바이오협회; 재생의료진흥재단; 한국규제과학센터; 한국병원약사회; 사단법인 한국에프디시규제과학회

학회/학교: 대한간학회; 대한감염학회; 대한암학회; 대한의학회; 대한임상약리학회; 대한항암요법연구회; 아주대학교 제약임상대학원; 한국임상개발연구회; 한국제약의학회; 대한소아혈액종양학회

정보서비스: 의약품통합정보시스템(식품의약품안전처); 국가건강정보포털(질병관리청); 임상연구정보서비스(질병관리청); 의료기기정보포털(식품의약품안전처); 제약산업정보포털(한국보건산업진흥원); 희귀질환헬프라인(질병관리청); 임상진료지침정보센터(대한의학회)

해외 유관 기관: 정부 규제기관; (미국) FDA(U.S. Food & Drug Administration); (중국) NMPA(National Medical Products Administration); (유럽) EMA(European Medicines Agency); (영국) MHRA(Medicines & Healthcare products Regulatory Agency); (캐나다) Health Canada; (호주) TGA(Therapeutic Goods Administration); (인도) CDSCO(Central Drugs Standard Control Organization); (일본) MHLW(Ministry of Health, Labour, and Welfare); (일본) PMDA(Pharmaceuticals & Medical Devices Agency); (싱가폴) HSA(Health Sciences Authority); (대만) TFDA(Taiwan Food and Drug Administration); (홍콩) DO(Drug Office); (태국) FDA Thailand; (베트남) DAV(Drug Administration of Vietnam); (인도네시아) NA-DFC(Indonesia National Agency of Drug and Food Control); (인도네시아) BPOM(Badan Pengawas Obat dan Makanan); 지원 기관; (미국) ACRES(Alliance for Clinical Research Excellence and Safety); (미국) AARHPP(Association for the Accreditation of Human Research Protection Program); (미국) ACRP(Association of Clinical Research Professionals); (미국) CenterWatch; (미국) DIA(Drug Information Association); (미국) NIH(National Institutes of Health); (미국) NCI(National Cancer Institute); (미국) MIT CRITICAL DATA; (미국) TransCelerate; (유럽) ECRIN(European Clinical Research Infrastructure Network); (영국) UKCRC(UK Clinical Research Collaboration); (영국) NIHR(National Institute for Health Research); (호주) Australian Clinical Trials; (일본) TRI(Translational Research Informatics Center); (일본) AMED(Japan Agency for Medical Research and Development); (싱가폴) SCRI(Singapore Clinical Research Institute); (네덜란드) IFAPP(International Federation of Associations of Pharmaceutical Physicians); (사우디아라비아) KAIMRC(King Abdullah International Medical Research Center)

* CRO 게재 기준: CRO자율등록 기관

ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.

전체 2550건이 검색되었습니다.


No.	Status	Study Title	Conditions	Interventions	Phase	Sponsor/Collaborators	Funder Type	Number Enrolled	Sex	Age	Locations
457	Completed	Study of COVID-19 DNA Vaccine (AG0302-COVID19)	COVID-19	Biological: AG0302-COVID19 Biological: AG0302-COVID19 Biological: AG0302-COVID19	Phase 2	AnGes, Inc.	INDUSTRY	30	All	20 Years ~ 65 Years	Osaka University Hospital, Osaka, Japan
456	Completed	Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients	COVID-19	Drug: CPI-006 Other: Standard of Care	Phase 1	Corvus Pharmaceuticals, Inc.	INDUSTRY	30	All	18 Years	El Centro Regional Medical Center, El Centro, California, United States Icahn School of Medicine at Mount Sinai, New York, New York, United States Temple University Hospital, Philadelphia, Pennsylvania, United States
455	Active, not recruiting	Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure	Acute Respiratory Distress Syndrome	Biological: Decidual Stromal Cells (DSC)	Not Applicable	University Health Network, Toronto, Oslo University Hospital	OTHER	19	All	18 Years ~ 75 Years	Brampton Civic Hospital, Brampton, Ontario, Canada Etobicoke General Hospital, Etobicoke, Ontario, Canada Toronto General Hospital, Toronto, Ontario, Canada
454	Recruiting	Study of Descartes-30 in Acute Respiratory Distress Syndrome	Covid19	Biological: Descartes 30	Phase 2	Cartesian Therapeutics	INDUSTRY	30	All	18 Years	University of Alabama at Birmingham, Birmingham, Alabama, United States University of California-Irvine, Irvine, California, United States University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States University of Maryland Medical Center Medical Center, Baltimore, Maryland, United States Brigham and Women's Hospital, Boston, Massachusetts, United States University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
453	Recruiting	Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients	Sickle Cell Disease (SCD)	Drug: Crizanlizumab	Phase 2	Novartis Pharmaceuticals	INDUSTRY	100	All	6 Months ~ 17 Years	University of Alabama 1600 7th ave, Birmingham, Alabama, United States Phoenix Childrens Hospital CVAL489A2302, Phoenix, Arizona, United States UC Davis Medical Center, Sacramento, California, United States Children s National Hospital, Washington, District of Columbia, United States University of Florida College of Medicine, Gainesville, Florida, United States Joe DiMaggio Childrens Hospital, Hollywood, Florida, United States Childrens Healthcare of Atlanta, Atlanta, Georgia, United States Ann and Robert H Lurie Childrens Hospital of Chicago CTBM100C2407, Chicago, Illinois, United States University of Chicago Hospital, Chicago, Illinois, United States Childrens Hospital Boston, Boston, Massachusetts, United States Childrens Hospital of Michigan, Detroit, Michigan, United States Institute for Pediatric Cancer and Blood Disorders, Hackensack, New Jersey, United States UMDNJ, New Brunswick, New Jersey, United States Children's Hospital at Montefiore, Bronx, New York, United States Duke University Medical Center Oncology, Durham, North Carolina, United States East Carolina University SC, Greenville, North Carolina, United States Children s Hospital of Philadelphia Patient Treatment, Philadelphia, Pennsylvania, United States Medical University of South Carolina Medical Uni of South Carolina, Charleston, South Carolina, United States St. Jude Children's Research Hosptial, Memphis, Tennessee, United States Cook Childrens Medical Center Oncology, Fort Worth, Texas, United States Novartis Investigative Site, Edegem, Antwerpen, Belgium Novartis Investigative Site, Brussel, Belgium Novartis Investigative Site, Laeken, Belgium Novartis Investigative Site, Liege, Belgium Novartis Investigative Site, Salvador, BA, Brazil Novartis Investigative Site, Ribeirao Preto, SP, Brazil Novartis Investigative Site, Sao Paulo, SP, Brazil Novartis Investigative Site, Toronto, Ontario, Canada Novartis Investigative Site, Montreal, Quebec, Canada Novartis Investigative Site, Medellin, Antioquia, Colombia Novartis Investigative Site, Cali, Valle Del Cauca, Colombia Novartis Investigative Site, Monteria, Colombia Novartis Investigative Site, Paris cedex 15, France Novartis Investigative Site, Heidelberg, Baden Wuerttemberg, Germany Novartis Investigative Site, Berlin, Germany Novartis Investigative Site, Nagpur, Maharashtra, India Novartis Investigative Site, New Delhi, India Novartis Investigative Site, Vellore, India Novartis Investigative Site, Modena, Italy Novartis Investigative Site, Orbassano, Italy Novartis Investigative Site, Padova, Italy Novartis Investigative Site, Beirut, Lebanon Novartis Investigative Site, Tripoli, Lebanon Novartis Investigative Site, Muscat, Oman Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain Novartis Investigative Site, Barcelona, Catalunya, Spain Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain Novartis Investigative Site, Madrid, Spain Novartis Investigative Site, Aarau, Aargau, Switzerland Novartis Investigative Site, Adana, Turkey Novartis Investigative Site, Mersin, Turkey Novartis Investigative Site, London, United Kingdom Novartis Investigative Site, London, United Kingdom Novartis Investigative Site, Manchester, United Kingdom
452	Active, not recruiting	Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects	Covid19	Biological: DS-5670a Biological: Placebo	Phase 2	Daiichi Sankyo Co., Ltd.	INDUSTRY	152	All	20 Years ~ 74 Years	SOUSEIKAI Hakata Clinic, Hakata, Fukuoka, Japan
451	Completed	Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia	Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia	Drug: Canakinumab Drug: Placebo	Phase 3	Novartis Pharmaceuticals	INDUSTRY	454	All	18 Years	Novartis Investigative Site, Birmingham, Alabama, United States Novartis Investigative Site, Glendale, California, United States Novartis Investigative Site, San Francisco, California, United States Novartis Investigative Site, San Francisco, California, United States Novartis Investigative Site, Chicago, Illinois, United States Novartis Investigative Site, Baltimore, Maryland, United States Novartis Investigative Site, Boston, Massachusetts, United States Novartis Investigative Site, Boston, Massachusetts, United States Novartis Investigative Site, Brooklyn, New York, United States Novartis Investigative Site, Chapel Hill, North Carolina, United States Novartis Investigative Site, Cleveland, Ohio, United States Novartis Investigative Site, Philadelphia, Pennsylvania, United States Novartis Investigative Site, Houston, Texas, United States Novartis Investigative Site, Richmond, Virginia, United States Novartis Investigative Site, Tacoma, Washington, United States Novartis Investigative Site, Toulouse Cedex 4, France Novartis Investigative Site, Bergamo, BG, Italy Novartis Investigative Site, Cona, FE, Italy Novartis Investigative Site, Barnaul, Russian Federation Novartis Investigative Site, Moscow, Russian Federation Novartis Investigative Site, Moscow, Russian Federation Novartis Investigative Site, Moscow, Russian Federation Novartis Investigative Site, Moscow, Russian Federation Novartis Investigative Site, Ryazan, Russian Federation Novartis Investigative Site, S-Petersburg, Russian Federation Novartis Investigative Site, Saint Petersburg, Russian Federation Novartis Investigative Site, Sestroretsk, Russian Federation Novartis Investigative Site, St Petersburg, Russian Federation Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain Novartis Investigative Site, Barcelona, Catalunya, Spain Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain Novartis Investigative Site, Madrid, Spain Novartis Investigative Site, Madrid, Spain Novartis Investigative Site, Madrid, Spain Novartis Investigative Site, Barnet, United Kingdom Novartis Investigative Site, Coventry, United Kingdom Novartis Investigative Site, Leeds, United Kingdom Novartis Investigative Site, London, United Kingdom Novartis Investigative Site, London, United Kingdom